Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Status:
Recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on
medication-induced gastrointestinal (GI) complications in patients with melanoma or
genitourinary cancer. The gut microbiome (the bacteria and microorganisms that live in the
digestive system) may affect whether or not someone develops colitis (inflammation of the
intestines) during cancer treatment with immune-checkpoint inhibitor drugs. Studying samples
of stool, blood, and tissue from patients with melanoma or genitourinary cancer may help
doctors learn more about the effects of treatment on cells, and help doctors understand how
well patients respond to treatment. Treatment with fecal transplantation may help to improve
diarrhea and colitis symptoms.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cortisone Cortisone acetate Immunoglobulin G Immunoglobulins Infliximab Prednisone Vedolizumab